Table 1.
Patient characteristics
| Characteristic | Median or N | Range or % |
|---|---|---|
| Sex | ||
| Male | 124 | 63.3% |
| Female | 72 | 36.7% |
| Age, y | 61 | 17-88 |
| WHO subtype | ||
| RA | 14 | 8.9% |
| RARS | 8 | 5.1% |
| RCUD | 5 | 3.2% |
| RCMD | 93 | 59.2% |
| RAEB-1 | 15 | 9.6% |
| RAEB-2 | 5 | 3.2% |
| MDS-U | 11 | 7.0% |
| Isolated 5q- | 6 | 3.8% |
| Complete blood count | ||
| White blood cell count | 2.4 | 0.1-26.4 |
| Absolute neutrophil count | 0.85 | 0-5.95 |
| Hemoglobin level | 8.9 | 5.3-12.8 |
| Platelet count | 44.5 | 0-1111 |
| Bone marrow blast % | 1.8 | 0-20 |
| Bone marrow cellularity % | 45 | 0-100 |
| Hypocellular bone marrow (<20%) | 22/82 | 26.8% |
| Peripheral blood blast % | 0 | 0-3.3 |
| IPSS | ||
| Low | 33 | 22% |
| Intermediate-1 | 104 | 69.3% |
| Intermediate-2 | 12 | 8% |
| High | 1 | 0.7% |
| LR-PSS | ||
| Risk category 1 | 38 | 25.3% |
| Risk category 2 | 62 | 41.3% |
| Risk category 3 | 50 | 33.3% |
| Molecular analysis | ||
| PNH clone (present/absent) (n = 62) | 16/46 | 26% |
| LGL clone (present/absent) (n = 44) | 16/28 | 36% |
| HLA-DR15 (positive/negative) (n = 52) | 28/24 | 54% |
| TP53 (mutated/nonmutated) (n = 43) | 2/41 | 5% |
| IDH1 (mutated/nonmutated) (n = 74) | 2/72 | 3% |
| IDH2 (mutated/nonmutated) (n = 39) | 0/39 | 0% |
| ASXL1 (mutated/nonmutated) (n = 41) | 6/35 | 15% |
| SF3B1 (mutated/nonmutated) (n = 73) | 10/63 | 14% |
LR-PSS, LR-MDS Prognostic Scoring System.